Renal accumulation of pentosidine in non-diabetic proteinuria-induced renal damage in rats

Nephrology Dialysis Transplantation

Volumn 20, Issue 10, 2005, Pages 2060-2070

  Waanders, Femke ^a   Greven, Wendela L ^a   Baynes, John W ^b   Thorpe, Suzanne R ^b   Kramer, Andrea B ^a   Nagai, Ryoji ^c   Sakata, Noriyuki ^d   van Goor, Harry ^a   Navis, Gerjan J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c KUMAMOTO UNIVERSITY   (Japan)

^d FUKUOKA UNIVERSITY   (Japan)

Author keywords

Adriamycin nephrosis; Advanced glycation end products; Angiotensin converting enzyme (ACE) inhibition; Immunohistochemistry; Maillard reaction; Nonenzymatic glycosylation

Indexed keywords

ADVANCED GLYCATION END PRODUCT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; LISINOPRIL; PENTOSIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOPLASM; DISEASE SEVERITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; KIDNEY COLLECTING TUBULE; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY TUBULE EPITHELIUM; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ARGININE; BLOOD PRESSURE; CHOLESTEROL; CREATININE; DOXORUBICIN; GLYCOSYLATION END PRODUCTS, ADVANCED; IMMUNOHISTOCHEMISTRY; KIDNEY; LISINOPRIL; LYSINE; MALE; PROTEINURIA; RATS; RATS, WISTAR;

EID: 27144488794     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfh939     Document Type: Article

References (21)

1. Tanji N, Markowitz GS, Fu C et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000; 11: 1656-1666
2. Beisswenger PJ, Makita Z, Curphey TJ et al. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995; 44: 824-829
3. Vlassara H, Striker LJ, Teichherg S et al. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994; 91: 11704-11708
4. Yamagishi S, Inagaki Y, Okamoto T et al. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Kidney Int 2003; 63: 464-473
5. Alderson NL, Chachich ME, Frizzell N et al. Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat. Diabetologia 2004; 47: 1385-1395
6. Miyata T, van Ypersele DS, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: Origin and significance of 'carbonyl stress' in long-term uremic complications. Kidney Int 1999; 55: 389-399
7. Alderson NL, Chachich ME, Youssef NN et al. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 2003; 63: 2123-2133
8. Miyata T. Ueda Y, Horie K et al. Renal catabolism of advanced glycation end products: The fate of pentosidine. Kidney Int 1998; 53: 416-422
9. Li YM, Steffes M, Donnelly T et al. Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci USA 1996; 93: 3902-3907
10. Henle T, Miyata T. Advanced glycation end products in uremia. Adv Ren Replace Ther 2003; 10: 321-331
11. Kitauchi T, Yoshida K, Yoneda T et al. Association between pentosidine and arteriosclerosis in patients receiving hemodialysis. Clin Exp Nephrol 2004; 8: 48-53
12. Wapstra FH, Van Goor H, Navis G, De Jong PE, De Zeeuw D. Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis. Clin Sci (Lond) 1996; 90: 393-401
13. De Boer E, Navis G, Tiebosch AT, De Jong PE, De Zeeuw D. Systemic factors are involved in the pathogenesis of proteinuria-induced glomerulosclerosis in adriamycin nephrotic rats. J Am Soc Nephrol 1999; 10: 2359-2366
14. Miyazaki K, Nagai R, Horiuchi S. Creatine plays a direct role as a protein modifier in the formation of a novel advanced glycation end product. J Biochem (Tokyo) 2002; 132: 543-550
15. Requena JR, Price DL, Thorpe SR, Baynes JW. Measurement of pentosidine in biological samples. Methods Mol Med 2000; 38: 209-217.
16. Nakamura S, Tachikawa T, Tobita K et al. An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats. Am J Kidney Dis 2003; 41: S68-S71
17. Uribarri J, Cai W, Peppa M, Goldberg T, Vlassara H. Renal clearance of advanced glycoxidation end products (AGE) is markedly reduced in diabetic patients in the absence of impaired GFR. J Am Soc Nephrol 2003; 14: 395A
18. Miyata T, van Ypersele DS, Ueda Y et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J Am Soc Nephrol 2002; 13: 2478-2487
19. Sebekova K, Schinzel R, Munch G et al. Advanced glycation end-product levels in subtotally nephrectomized rats: Beneficial effects of angiotensin II receptor 1 antagonist losartan. Miner Electrolyte Metab 1999; 25: 380-383
20. Davis BJ, Forbes JM, Thomas MC et al. Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia 2004; 47: 89-97
21. Wendt TM, Tanji N, Guo J et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162: 1123-1137